Market Overview

Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Related JNJ
Johnson & Johnson Posts Upbeat Q3 Earnings, But Sales Drop
US Stock Futures Down; JPMorgan Earnings In Focus
J&J Q3 top line off 7%; net income down 29%; full-year EPS guidance raised (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”

Johnson & Johnson closed on Friday at $103.73.

Latest Ratings for JNJ

Sep 2015Deutsche BankUpgradesHoldBuy
Sep 2015UBSInitiates Coverage onBuy
Aug 2015JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (JNJ)

Get Benzinga's Newsletters